GINECO Prospective Non-interventional PROSPECTYON Study: Trabectedin Plus Pegylated Liposomal Doxorubicin for Platinum-sensitive Recurrent Ovarian Cancer.
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Ovarian Epithelial
/ drug therapy
Cohort Studies
Doxorubicin
/ administration & dosage
Female
Humans
Middle Aged
Neoplasm Recurrence, Local
/ drug therapy
Organoplatinum Compounds
/ pharmacology
Ovarian Neoplasms
/ drug therapy
Polyethylene Glycols
/ administration & dosage
Prospective Studies
Trabectedin
/ administration & dosage
Ovarian cancer
pegylated liposomal doxorubicin
platinum-sensitive
trabectedin
Journal
Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
24
04
2020
revised:
18
05
2020
accepted:
22
05
2020
entrez:
5
7
2020
pubmed:
6
7
2020
medline:
6
8
2020
Statut:
ppublish
Résumé
Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice. Patients with ROC after at least one platinum-based regimen received 1.1 mg/m Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups. Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.
Sections du résumé
BACKGROUND
BACKGROUND
Trabectedin and pegylated liposomal doxorubicin (PLD) is an effective combination therapy for platinum-sensitive recurrent ovarian cancer (ROC), particularly for disease relapsing within 6-12 months of platinum therapy. The non-interventional PROSPECTYON study evaluated trabectedin/PLD in French clinical practice.
PATIENTS AND METHODS
METHODS
Patients with ROC after at least one platinum-based regimen received 1.1 mg/m
RESULTS
RESULTS
Recurrent disease was partially platinum-sensitive in 58 patients and fully sensitive in 33 patients treated between July 2014 and June 2016. Patients in both subgroups received a median of six cycles of trabectedin and PLD. The most common grade 3 or more toxicities were haematological. Median progression-free survival was 6 months for both subgroups.
CONCLUSION
CONCLUSIONS
Trabectedin/PLD is a valuable treatment option for partially or fully platinum-sensitive ROC.
Identifiants
pubmed: 32620635
pii: 40/7/3939
doi: 10.21873/anticanres.14385
doi:
Substances chimiques
Organoplatinum Compounds
0
liposomal doxorubicin
0
Polyethylene Glycols
3WJQ0SDW1A
Doxorubicin
80168379AG
Trabectedin
ID0YZQ2TCP
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
3939-3945Informations de copyright
Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.